TORONTO, Sept. 29, 2014 /PRNewswire/ - SQI Diagnostics
Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that
develops and commercializes proprietary technologies and products
for advanced microarray diagnostics, is pleased to announce the
appointment of Peter Winkley to
Chairman of the Board of Directors of SQI, replacing Claude Ricks. Mr. Ricks will continue to
serve as a Director on the Board and will continue to provide
leadership to the Company.
"We are very pleased to have Mr. Winkley assume the role of
chairman", said Andrew Morris
President and CEO. "Peter's years in the industry,
independence, and governance experience will be fully utilized in
this new role. I would also like to thank Claude for his
important contributions as Chairman and for his continued support
to the development of SQI."
Mr. Winkley is a CPA, CA and is the Vice-President, Finance and
Chief Financial Officer of Algoma Central Corporation and has been
a board member of SQI Diagnostics since 2007. Mr. Winkley
will continue to serve as chairman of the Audit Committee. Prior to
joining Algoma Central, he was V.P., Finance and CFO of Therapure
Biopharma Inc., a Mississauga-based biologics contract
manufacturer. Peter began his career in the corporate audit
practice of Ernst & Young LLP before going on to lead the
Corporate Finance function for MDS Inc. Peter has extensive
experience with public company financial reporting and governance,
treasury, risk management and corporate finance.
About SQI Diagnostics
SQI Diagnostics is a life
sciences and diagnostics company that develops and commercializes
proprietary technologies and products for advanced microarray
diagnostics. The Company's proprietary microarray tests and
fully-automated systems are designed to simplify protein and
antibody testing workflow, increase throughput, reduce costs and
provide excellent data quality. For more information, please visit
www.sqidiagnostics.com.
Forward-looking Information
This news release
contains certain forward-looking statements, including, without
limitation, statements containing the words "will", "expects",
"intends" and other similar expressions which constitute
"forward-looking information" within the meaning of applicable
securities laws. Forward-looking statements reflect the Company's
current expectation and assumptions, and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to
general economic and market segment conditions, and international
risk and currency exchange, agreements and future agreements to
sell our products, the acceleration of our revenue ramp, general
economic and market segment conditions. Such statements reflect the
current views of the Company with respect to future events and are
subject to certain risks and uncertainties and other risks detailed
from time-to-time in the Company's ongoing filings with the
securities regulatory authorities, which filings can be found at
www.sedar.com. Actual results, events, and performance may differ
materially. Readers are cautioned not to place undue reliance on
these forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.